TY - T1的临床分级exha的效用led nitric oxide in severe asthma management JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01633-2019 VL - 55 IS - 3 SP - 1901633 AU - Menzies-Gow, Andrew AU - Mansur, Adel H. AU - Brightling, Christopher E. Y1 - 2020/03/01 UR - //www.qdcxjkg.com/content/55/3/1901633.abstract N2 - Asthma is a chronic inflammatory disease of the airways, affecting over 350 million people worldwide and placing a significant burden on healthcare providers and wider society. Approximately 5–10% of asthma patients are diagnosed with severe asthma and typically are associated with increased risk of hospitalisation from exacerbations, increased morbidity, mortality and higher asthma-associated healthcare costs. Nitric oxide (NO) is an important regulator of immune responses and is a product of inflammation in the airways that is over-produced in asthma. Fractional exhaled NO (FeNO) is predominantly used as a predictor of response to inhaled corticosteroids (ICSs), to monitor adherence and as a diagnostic tool in ICS-naïve patients. In the UK, the National Institute for Health and Care Excellence (NICE) guidelines recommend the use of FeNO for the initial diagnosis of patients with suspected asthma. In the USA, American Thoracic Society (ATS) guidelines recommend FeNO as part of the initial diagnosis of asthma and for monitoring of airway inflammation. FeNO has also been shown to be a predictive factor for asthma exacerbations, with higher levels being associated with a greater number of exacerbations. In addition, higher levels of FeNO have been shown to be associated with a decline in lung function. FeNO testing is a cost-effective procedure and has been shown to improve patient management when combined with standard assessment methods. Recent evidence suggests that FeNO may also be useful as a surrogate biomarker for the assessment and management of severe asthma and to predict responsiveness to some biological therapies.The optimisation of FeNO testing methods in a variety of clinical settings, as a non-invasive, readily available, and affordable technology, could play an important role in advancing effective asthma control http://bit.ly/2FN6P3j ER -